Sergio Cifuentes, Cancer Research Project Manager at
”KEYNOTE-A18.
- Pembrolizumab + CRT in LACC
- mPFS NR in pembrolizumab group
24m PFS: 68% vs 57%
- Pembrolizumab + CRT led to a 30% reduction in DR
- OS at 24m: 87% vs 81%
Grade 3 or higher AE: 75% vs 69%.”
Read further.
Source: Sergio Cifuentes/X